Investigation of the Molecular Mechanisms of Sanguinaria canadensis in Treating Lung Cancer Using Network Pharmacology and Molecular Docking Techniques

This study examines the molecular mechanism that underlies the possible therapeutic benefits of Sanguinaria canadensis in the treatment of lung cancer. Through network pharmacology and molecular docking techniques, we identify 15 bioactive compounds from S. canadensis, with sanguinarine and chelerythrine being the most prominent. These compounds interact with key proteins involved in lung cancer progression, including IL-6, IL-1β, ICAM1, TNF, and MMP-9. Pathway enrichment analysis reveals significant involvement of pathways such as homologous recombination, p53 signaling, and cell cycle. GO and KEGG analyses elucidate the molecular mechanisms underlying cancer pathogenesis and highlight potential therapeutic targets. STING enrichment analysis uncovers crucial biological processes associated with STING-regulated genes, suggesting their involvement in cancer-related functions. Molecular docking studies demonstrate strong binding affinities between bioactive compounds and target proteins, indicating potential efficacy in impeding cancer-related processes. This comprehensive investigation provides insights into the therapeutic potential of S. canadensis in lung cancer treatment, warranting further experimental validation and exploration of novel therapeutic strategies.